Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-1,05
KB0,30
PKN82,1482,150,46
Msft492,6492,61-0,96
Nokia4,3864,5-0,27
IBM292,08292,23-0,88
Mercedes-Benz Group AG49,27549,285-0,67
PFE25,0525,063,34
01.07.2025 20:22:36
Indexy online
AD Index online
select
AD Index online
 

  • 01.07.2025 20:21:44
Ginkgo Bio Rg-A (NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
11,60 3,11 0,35 1 421 476
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.07.2025
Popis společnosti
Obecné informace
Název společnostiGinkgo Bioworks Holdings Inc
TickerDNA
Kmenové akcie:Ordinary Shares Class A
Kmenové akcie:Ordinary Shares Class B
Kmenové akcie:Ordinary Shares Class C
RICDNA
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 31.12.2023 1 218
Akcie v oběhu k 05.11.2024 57 478 905
MěnaUSD
Kontaktní informace
Ulice27 Drydock Avenue, 8Th Floor
MěstoBOSTON
PSČ02210
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 102 097 280
Fax13026555049

Business Summary: Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Ginkgo Bioworks Holdings Inc revenues decreased 15% to $183.2M. Net loss decreased 35% to $439.5M. Revenues reflect Biosecurity segment decrease of 56% to $44M. Lower net loss reflects Not Allocated segment loss decrease of 86% to $54.3M, Cell Engineering segment loss decrease of 60% to $125.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$14.08 to -$8.62.
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 01.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Operating Officer, DirectorReshma Shetty4301.01.2021
Chief Executive Officer, DirectorJason Kelly4301.01.2021
Chief Financial OfficerMark Dmytruk5201.01.2021